Cochlear relieves Demant of loss-making implant division

Until now, Oticon Medical has been ”strategically important” for Demant, but hasn’t performed on par with expectations. Consequently, the subsidiary will be divested from its parent company, whose CEO says the deal made with the Australian firm is sound.

Photo: Jens Dresling

It is ostensibly not a growing business leg being removed from its parent company.

Danish hearing aid manufacturer Demant is getting rid of its subsidiary Oticon Medical, selling it for DKK 850m (USD 121.5m) to Australian hearing implant firm Cochlear.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs